BioSpace News Archive

Kiniksa P harmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis, a chronic inflammatory skin condition characterized by severely pru

Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces financial results for the second quarter ended September 30, 2020 and provides a corporate update. Recent and Second Quarter Highlights include: In-licensed global rights to Healthimati

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the Jefferies Virtual London Healthcare Conference on Wednesday,

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference: Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 Lonnel Coats, Lexicon’s president and chief executive officer, and Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat on Wednesday, November 18

KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced that Thijs Spoor, Chief Executive Officer, will participate in the following upcoming virtual investor conferences: Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 Presentation time: 1:20

Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has established a subsidiary, Digestix Bioscience Inc., a company dedicated to the development of medical devices and pharmace

Grant awarded to CHOP and Gustave Roussy to support phase 3 clinical trial developed by Children’s Oncology Group and International Society of Paediatric Oncology Europe Neuroblastoma Group, representing first-ever collaboration between North American and European neuroblastoma consortia

Internationally Renowned Med. Dents. and entrepreneurs Golnar and Haleh Abivardi unveil a suite of sustainably produced oral care products supercharged with the first tooth whitener that is actually good for your teeth.

Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”) , a precision oncology molecular profiling company with a novel phosphoprotein-based laboratory developed test (LDT), today announced its partnership with Perthera , a market leader in Precision Oncology technology and services. The alliance will facilitate and accele